CTLA4 and immune system disorder: Toxicity phenotype varied by age (more nervous/immune-system disorders in older adults; more hepatobiliary/hematologic events in younger adults), by sex (more endocrine events in women; more respiratory/vascular events in men), and, most strongly, by regimen: CTLA-4-containing schedules showed the severest profiles, whereas PD-1/PD-L1 monotherapy (e.g., in NSCLC) showed a better safety outcome.